A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder

European Urology

Volumn 54, Issue 4, 2008, Pages 740-764

  Novara, Giacomo ^a   Galfano, Antonio ^b   Secco, Silvia ^b   D'Elia, Carolina ^b   Cavalleri, Stefano ^b   Ficarra, Vincenzo ^b   Artibani, Walter ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Darifenacin; Detrusor overactivity; Emepronium; Fesoterodine; Muscarinic receptor antagonist; Overactive bladder; Oxybutynin; Propantheline; Propiverine; Solifenacin; Tolterodine; Trospium; Urgency frequency syndrome

Indexed keywords

DARIFENACIN; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PROPANTHELINE BROMIDE; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; HEADACHE; HUMAN; MEDICAL LITERATURE; META ANALYSIS; MICTURITION; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUSTAINED RELEASE FORMULATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY URGENCY; URINE INCONTINENCE; VISUAL IMPAIRMENT; XEROSTOMIA;

BENZHYDRYL COMPOUNDS; CRESOLS; HUMANS; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINARY BLADDER, OVERACTIVE;

EID: 50849116095     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.080     Document Type: Review

References (68)

1. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50 (2006) 1306-1315
2. Chapple C.R. Advancing the management of overactive bladder: new data, new directions. Eur Urol Suppl 6 (2007) 1-3
3. Reeves P., Irwin D., Kelleher C., et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50 (2006) 1050-1057
4. Klotz T., Brüggenjürgen B., Burkart M., and Resch A. The economic costs of overactive bladder in Germany. Eur Urol 51 (2007) 1654-1663
5. Toozs-Hobson P., and Latthe P. Critical evaluation of the efficacy and safety of anticholinergics in overactive bladder. Eur Urol Suppl 6 (2007) 425-431
6. Hampel C. Long-term management of overactive bladder with antimuscarinic agents. Eur Urol Suppl 6 (2007) 432-437
7. Abrams P., and Andersson K.E. Muscarinic receptor antagonists for overactive bladder. BJU Int 100 (2007) 987-1006
8. Chapple C., Khullar V., Gabriel Z., and Dooley J.A. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48 (2005) 5-26
9. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;18:CD003781.
10. Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005;3:CD005429.
11. Jadad A.R. Randomised controlled trials (1998), BMJ Publishing Group, London
12. Rothstein H.R., Sutton A.J., and Borenstein M. Publication bias in meta-analysis: prevention, assessment and adjustment (2005), John Wiley & Sons, Ltd, Chichester, UK
13. Nilsson C.G., Lukkari E., Haarala M., Kivelä A., Hakonen T., and Kiilholma P. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourol Urodyn 16 (1997) 533-542
14. Versi E., Appell R., Mobley D., Patton W., Saltzstein D., and The Ditropan XL Study Group. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 95 (2000) 718-721
15. Barkin J., Corcos J., Radomski S., et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 26 (2004) 1026-1036
16. Corcos J., Casey R., Patrick A., et al. A double-blind randomized dose-response study comparing daily doses of 5 mg, 10 mg, and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 97 (2006) 520-527
17. Jünemann K.P., Hessdörfer E., Unamba-Oparah I., et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int 77 (2006) 334-339
18. Jonas U., Höfner K., Madersbacher H., Holmdahl T.H., and The International Study Group. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 15 (1997) 144-151
19. Rentzhog L., Stanton S.L., Cardozo L., Nelson E., Fall M., and Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol 81 (1998) 42-48
20. Millard R., Tuttle J., Moore K., et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 161 (1999) 1551-1555
21. Jacquetin B., and Wyndaele J. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol 98 (2001) 97-102
22. Malone-Lee J.G., Walsh J.B., and Maugourd M.F. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 49 (2001) 700-705
23. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., Wein A., and The Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57 (2001) 414-421
24. Swift S., Garely A., Dimpfl T., Payne C., and The Tolterodine Study Group. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 14 (2003) 50-54
25. Cardozo L., Lisec M., Millard R., et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172 (2004) 1919-1924
26. Chapple C.R., Rechberger T., Al-Shukri S., et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93 (2004) 303-310
27. Chapple C.R., Cardozo L., Steers W.D., and Govier F.E. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 60 (2006) 959-966
28. Chapple C., Steers W., Norton P., et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 95 (2005) 993-1001
29. 3 selective receptor antagonist. Eur Urol 48 (2005) 471-477
30. Zinner N., Tuttle J., and Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 23 (2005) 248-252
31. Hill S., Khullar V., Wyndaele J.J., Lheritier K., and The Darifenacin Study Group. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 17 (2006) 239-247
32. Nitti V, Wiatrak M, Kreitman L, Lipsitz D. Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB): results of a phase 2 trial. ICS annual meeting; 2005. Abstract 306. Available at https://www.icsoffice.org/publications/2005/PDF/0306.PDF.
33. Chapple C., Van Kerrebroeck P., Tubaro A., et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52 (2007) 1204-1212 Corrigendum. Eur Urol 2008;53:1319
34. Nitti V.W., Dmochowski R., Sand P.K., et al. Efficacy, safety, and tolerability of fesoterodine for overactive bladder syndrome. J Urol 178 (2007) 2488-2494
35. Anderson R.U., Mobley D., Blank B., Saltzstein D., Susset J., Brown J.S., and OROS Oxybutynin Study Group. Once-daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. Urology 161 (1999) 1809-1812
36. Birns J., Lukkari E., and Malone-Lee J.G. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 85 (2000) 793-798
37. Abrams P., Cardozo L., Chapple C., Serdarevic D., Hargreaves K., Khullar V., and The 1032 Study Group. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 13 (2006) 692-698
38. Burton G. A randomized crossover trial comparing oxybutynin taken three times a day or taken "when needed". Neurourol Urod 13 (1994) 351-352 abstract
39. Sussman D., and Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 18 (2002) 177-184
40. Mazur D., Wehnert J., Dorschner W., Schubert G., Herfurth G., and Alken R.G. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study. Scand J Urol Nephrol 29 (1995) 289-294
41. Gittelman MC, Kaufman J. Solifenacin succinate 10 mg once daily significantly improves symptoms of overactive bladder. Presented at the 17th International Federation of Gynecology and Obstetrics World Congress, Abstract 111. November 2-7, 2003; Santiago, Chile.
42. Gittelman M. The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study. Int J Gynaecol Obstetr 83 Suppl 3 (2003) 94
43. Staskin D.R., and Te A.E. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU Int 97 (2006) 1256-1261
44. Cardozo L., Castro-Diaz D., Gittelman M., Ridder A., and Huang M. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 17 (2006) 512-519
45. Van Kerrebroeck E.V., Serment G., and Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. Neurourol Urod 16 (1997) 478-479 abstract #91
46. Abrams P., Freeman R., Anderström C., and Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81 (1998) 801-810
47. Drutz H.P., Appell R.A., Gleason D., Klimberg I., and Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 10 (1999) 283-289
48. Appell R.A., Sand P., Dmochowski R., et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 76 (2001) 358-363
49. Malone-Lee J., Shaffu B., Anand C., and Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 165 (2001) 1452-1456
50. Lee J.G., Hong J.Y., Choo M.S., et al. Tolterodina: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 90 (2002) 247-252
51. Diokno A.C., Appell R.A., Sand P.K., et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 78 (2003) 687-695
52. Homma Y., Paick J.S., Lee J.G., Kawabe K., Japanese, and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 92 (2003) 741-747
53. Giannitsas K., Perimenis P., Athanasopoulos A., Gyftopoulos K., Nikiforidis G., and Barbalias G. Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur Urol 46 (2004) 776-783
54. Homma Y., and Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 22 (2004) 251-256
55. Madersbacher H., Halaska M., Voigt R., Alloussi S., and Höfner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84 (1999) 646-651
56. Halaska M., Ralph G., Wiedemann A., et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20 (2003) 392-399
57. Junemann K.P., and Al-Shukri S. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double blind, placebo-controlled, multicentre clinical trial. Neurourol Urodynam (2000) 488-490 abstract
58. Jünemann K.-P., Halaska M., Rittstein T., et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 48 (2005) 478-482
59. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48 (2005) 464-470
60. Chapple C.R., Fianu-Jonsson A., Indig M., et al. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 52 (2007) 1195-1203
61. Thüroff J.W., Bunke B., Ebner A., et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145 (1991) 813-816
62. Leung H.Y., Yip S.K., Cheon C., et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. BJU Int 90 (2002) 375-380
63. Altan-Yaycioglu R., Yaycioglu O., Aydin Akova Y., Guvel S., and Ozkardes H. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol 59 (2005) 588-592
64. Davila G.W., Daugherty C.A., Sanders S.W., and Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 166 (2001) 140-145
65. Dmochowski R.R., Sand P.K., Zinner N.R., Gittelman M.C., Davila G.W., Sanders S.W., and Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62 (2003) 237-242
66. Cartwright R., and Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur Urol 51 (2007) 907-914
67. Colli E., Parazzini F., Olivieri L., et al. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials. Eur Urol 52 (2007) 525-530
68. Oxman A.D., and Guyatt G.H. Validation of an index of the quality of review articles. J Clin Epidemiol 44 (1991) 1271-1278